Reply Sir, We read with great interest the letter responding to our recently published article [1] . The authors describe a 66-year-old female renal transplant recipient who developed post-transplant dyslipidaemia after cyclosporine was switched to sirolimus, which was treated with fluvastatin. Two weeks later, she presented with sepsis and severe rhabdomyolysis requiring dialysis. The authors conclude that the rhabdomyolysis was possibly related to a drugdrug interaction between sirolimus and fluvastatin. Sirolimus is known to cause dyslipidaemia post-transplant, which may result in the addition or increased dosing of lipid-lowering therapy. In a trial using a sirolimus maintenance immunosuppressive regimen, resulting dyslipidaemia required statin and fibrate drug use in 80% and 25% of patients, respectively, compared with a baseline frequency of use of 15% and 3% [2] . Sirolimus and fluvastatin are both metabolized in part via the cytochrome P450 3A4 (cyp3A4) pathway, although fluvastatin relies on this pathway to less of an extent than other statins, and is thought to be relatively safe when used in combination with cyclosporine in renal transplant recipients [3] .
